News | 02.12.20
Study Reports Impact of Diabetes on 5-Year Outcomes After Endovascular Therapy for PAD
February 12, 2020—Findings from a study evaluating the long-term impact of diabetes mellitus in patients with peripheral artery disease (PAD) who underwent endovascular therapy were published by Michael S. Lee, MD, et al in Vascular Medicine (2020;25:33–40).
News | 01.30.20
Real-World Data Presented for VentureMed’s Flex Vessel Prep System to Treat Long CTOs
January 30, 2020—VentureMed Group, Inc. announced that data for the company’s Flex vessel preparation (VP) system were presented at ISET 2020, the International Symposium on Endovascular Therapy held January 22–25 in Hollywood, Florida.
News | 01.29.20
Interim Long-Term Safety Data Presented for BD’s Lutonix 014 DCB in BTK Arteries
January 29, 2020—BD (Becton, Dickinson and Company) announced the presentation of interim findings from the Lutonix BTK investigational device exemption trial of the company’s Lutonix 014 drug-coated balloon (DCB) versus standard balloon angioplasty for treatment of below-the-knee (BTK) arteries.
News | 01.28.20
One-Year COMPARE Data Show Similar Efficacy and Safety for High- and Low-Dose Paclitaxel-Coated Balloons for PAD Treatment
January 28, 2020—One-year data from the COMPARE trial comparing the use of high- versus low-dose paclitaxel-coated balloons in femoropopliteal interventions were presented by Sabine Steiner, MD, at LINC 2020, the Leipzig Interventional Course held January 28–31 in Leipzig, Germany.
News | 01.28.20
One-Year TINTIN Data Presented for iVascular’s Luminor DCB and iVolution Stent
January 28, 2020—iVascular, based in Barcelona, Spain, announced that 1-year clinical outcomes of the TINTIN trial were presented by Principal Investigator Koen Deloose, MD, at LINC 2020, the Leipzig Interventional Course held January 28–31 in Leipzig, Germany.
News | 01.16.20
PATHFINDER I Registry Will Study AngioDynamics’ Auryon Atherectomy System
January 16, 2020—AngioDynamics, Inc. announced the launch of the PATHFINDER I postmarket registry, which will enroll a total of 100 patients with peripheral artery disease (PAD) treated with the company’s Auryon atherectomy system in a postmarket setting with 36-month follow-up.
News | 01.15.20
Vascular Medicine Consult Registry Launched for the SVS Vascular Quality Initiative
January 15, 2020—The Society for Vascular Surgery (SVS), the SVS Vascular Quality Initiative (VQI), and the American Heart Association (AHA) announced the introduction of the Vascular Medicine Consult (VMC) registry for the VQI—a collaboration of the SVS Patient Safety Organization (PSO), the Society for Vascular Medicine, and AHA.
News | 01.15.20
New Paclitaxel Meta-Analysis Questions Safety in CLI Population; Concerns Voiced as to Methods
January 15, 2020—In the wake of a year spent scrutinizing the finding of a mortality signal related to paclitaxel-coated balloons and stents in the superficial femoral artery (SFA), a new publication again calls the safety of paclitaxel into question, only this time in the critical limb ischemia (CLI) population.
News | 01.13.20
Insurance Data From Large Patient Cohort Used to Analyze Peripheral Arterial Occlusive Disease in Germany
January 13, 2020—Treatment and comorbidity patterns among patients with peripheral arterial occlusive disease (PAOD) were evaluated using up-to-date longitudinal patient-related data from health insurance claims in Germany.
News | 01.13.20
German Analysis Shows Long-Term Survival With Paclitaxel-Coated Devices Used for Femoropopliteal Artery Revascularization
January 13, 2020—The rapid adoption of the use of paclitaxel-coated devices to treat patients with chronic limb-threatening ischemia (CLTI) has resulted in higher long-term survival, better amputation-free survival, and lower rates of major cardiovascular events, concluded investigators of a retrospective, propensity score-matched cohort analysis of German health insurance claims.
News | 12.13.19
Randomized Controlled Trial Compares Nitinol Stents Versus Bypass in Long Femoropopliteal Lesions
December 13, 2019—Investigators from Paracelsus Medical University in Salzburg, Austria, conducted a study that sought to compare patency rates and clinical outcomes of endovascular therapy using nitinol stents and primary vein bypass in long femoropopliteal lesions.
News | 11.20.19
Two-Year ZILVERPASS Data Compares Cook Medical's Zilver PTX Versus Surgery
November 20, 2019—Cook Medical announced data supporting the use of the company’s Zilver PTX paclitaxel-coated stent for the treatment of peripheral artery disease (PAD) were presented by Marc Bosiers, MD, at the VEITHsymposium held November 19–23 in New York, New York.
News | 11.14.19
European Societies Publish Consensus Document on Follow-Up After Revascularization for PAD
November 14, 2019—A consensus document from European societies on the follow-up of patients after revascularization for peripheral artery disease (PAD) was published by Maarit Venermo, MD, et al in the European Journal of Vascular and Endovascular Surgery (2019;58:641–653).
News | 11.06.19
Twelve-Month Outcomes Presented From Mercator MedSystems' TANGO Trial
November 6, 2019—VIVA Physicians announced the presentation of initial 12-month outcomes of the TANGO trial , a phase 2, dose-escalation, double-blinded trial comparing the delivery of temsirolimus versus saline in patients with severe claudication or critical limb ischemia, with the purpose of limiting neointimal hyperplastic tissue growth into the artery after endovascular below-the-knee (BTK) revascularization procedures.
News | 11.05.19
One-Year MIMICS-3D Registry Results Support Veryan's BioMimics 3D Stent
November 5, 2019—VIVA Physicians announced that 1-year results from the European MIMICS-3D registry, evaluating the BioMimics three-dimensional (3D) nitinol stent (Veryan Medical Ltd.), were presented by Michael Lichtenberg, MD, during a late-breaking clinical trial session at VIVA 2019, the Vascular InterVentional Advances meeting held November 4–7 in Las Vegas, Nevada.
News | 11.05.19
VMI-CFA Data Support Durability of Endovascular Treatment of Common Femoral Artery at 24 Months
November 5, 2019—VIVA Physicians announced that 24-month safety and efficacy results from the full-cohort of the VMI-CFA trial were presented by Koen Deloose, MD, in a late-breaking clinical trial session at VIVA 2019, the Vascular InterVentional Advances meeting held November 4–7 in Las Vegas, Nevada.
US Device Guide
This Device Guides offers a searchable, comprehensive listing of the available vascular interventional devices in the United States.
European Device Guide
This Device Guides offers a searchable, comprehensive listing of the available vascular interventional devices in Europe.